AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wirden, M.
Right arrow Articles by Calvez, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wirden, M.
Right arrow Articles by Calvez, V.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2004, p. 644-647, Vol. 48, No. 2
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.2.644-647.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Comparison of the Dynamics of Resistance-Associated Mutations to Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors after Cessation of Antiretroviral Combination Therapy

Marc Wirden,1* Constance Delaugerre,1 Anne Genevieve Marcelin,1 Nadine Ktorza,2 Hocine Ait Mohand,2 Stephanie Dominguez,2 Luminita Schneider,2 Jade Ghosn,2 Michele Pauchard,2 Dominique Costagliola,3 Christine Katlama,2 and Vincent Calvez1

Departments of Virology,1 Infectious Diseases,2 INSERM EMI 0214, Pitié-Salpêtrière Hospital, Paris, France3

Received 1 July 2003/ Returned for modification 26 August 2003/ Accepted 4 November 2003

The dynamics of mutations associated with resistance to antiretroviral drugs were analyzed after cessation of therapy. The results showed that the kinetics of the shift to wild-type amino acid residues were significantly faster for protease inhibitors, intermediate for nonnucleoside reverse transcriptase inhibitors, and slower for nucleoside reverse transcriptase inhibitors.

* Corresponding author. Mailing address: CERVI, Department of Virology, Pitié-Salpêtrière Hospital, 83 bd. de l'Hôpital, Paris 75013, France. Phone: 33-142177401. Fax: 33-142177411. E-mail: marc.wirden{at}psl.ap-hop-paris.fr.

Antimicrobial Agents and Chemotherapy, February 2004, p. 644-647, Vol. 48, No. 2
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.2.644-647.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2004 by the American Society for Microbiology. All rights reserved.